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ABSTRACT 
Although adenoviral vectors are attractive for gene transfer, their effectiveness is limited by host antiviral im-
m u n e responses. In this study, w e determined if host antiallograft and antiviral immunity could be dimin-
ished with an adenoviral vector encoding the immunosuppressive cytokine viral interleukin-10 (vIL-IO). 
AdSV40vIL-10, a vIL-10-expressing adenoviral vector with an SV40 promoter, induced significant prolonga-
tion of murine cardiac allograft survival to 32.2 ± 1.7 days compared to 14.2 ± L O days for controls (p < 
O.OI). This effect was specific for vIL-IO encoding vector and could be inhibited by anti-vIL-10 monoclonal 
antibody ( m A b ) . In vivo administration of adenovirus facilitated the generation of adenovirus-specific cyto-
toxic T lymphocytes (CTL), whereas treatment vdth AdSV40vIL-10 prevented C T L priming and generation 
of virus-specific immunity. AdSV40vIL-I0 also induced extended expression of a /3-galactosidase reporter 
from a co-injected LacZ-encoding adenoviral vector. These results demonstrate that adenovirus-mediated gene 
transfer and expression of vIL-10 prolong allograft survival and inhibit the immune response to adenoviral 
antigens, thereby improving the persistence of the vector and extending transgene expression. The efficacy of 
adenoviral vectors can be improved by incorporating immunosuppressive genes into the vector. 
OVERVIEW SUMMARY INTRODUCTION 
Adenoviral vectors are efficient for in vivo delivery of genes TNTERLEtJiaN-10 (IL-IO) was originally described as cytoldne 
to a wide variety of tissue types, whereas the duration of ex- Xsyntiiesis inhibitory factor (Moore ef al, 1990) and is able to 
pression is limited by the potent adenovirus-specific im- regulate negatively a variety of immune responses. IL-10 is pro-
mune response directed to the infected cell. In this study, duced by macrophages and TH2 ceUs and inhibits tiie syntiiesis 
we demonstrate that adenovirus-mediated gene transfer of cytokines by THI ceUs (de Waal Malefyt ef al, 1991a; Taga 
and expression of viral interleukin-10 (vIL-10) not only pro- andTosato, 1992; Del etal, 1993), particularly interferon-̂ (IFN-
longs murine cardiac aUograft survival, but also inhibits the y). IL-10 sttongly downregulates class H major histocompatibU-
immune response toward adenoviral antigens, and thereby ity complex (MHC) expression on monocytes (de Waal Malefyt 
improves the persistence of the vector and extends trans- ef al, 1991b), which is particularly important for antigen pre-
gene expression. These findings could be used to design a sentation. IL-10 also inhibits antigen-presenting ceU (APC) fiinc-
new generation of adenoviral vector that expresses botii an tions (Ding et al, 1992, 1993; Enk ef al, 1993); and flie pro-
immunosuppressive cytokine gene and another gene of m- duction of monokines (Fiorentino ef al, 1991; Ralph ef al, 1992; 
terest. This strategy should have general application in CassateUa ef al, 1993; Scott 1993; Tripp ef al, 1993), such as 
many gene therapy settings other than transplantation. IL-8 (CassateUa ef al, 1993), mmor necrosis factor-a (TNF-a) 
Nonetheless, although the efficacy of adenoviral vectors can (Ralph ef al, 1992), and IL-12 (Tripp ef al, 1993), an initiation 
be improved by incorporating immunosuppressive genes cytokine for THI ceU differentiation and cell-mediated immu-
into the vector, there are also nonimmune mechanisms serv- nity (Scott, 1993). IL-10 also has growtii factor activities for a 
ing to limit vector gene expression. variety of cell types (Go ef al, 1990; Chen and Zlotnik, 1991; 
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Thompson ef al, 1991; Rousset 1992). Viral IL-10, a product en-
coded by tiie Epstein-Barr virus (EBV) B C R F 1 open reading 
frame, is homologous to botii murine and human IL-10, espe-
ciaUy in tiie coding region of the mature protein sequence (Hsu 
ef al, 1990; Moore ef al, 1990; Vieira ef al, 1991). Vkal IL-10 
shares many biological properties witii murine and human R.-10, 
including cytokine syntiiesis inhibitory factor activity and down-
regulation of class n M H C expression on monocytes (Hsu ef al, 
1990; de Waal Malefyt ef al, 1991b; Vieira ef al, 1991). Vual 
IL-10, however, does not possess tiie T ceU co-stimulatory ac-
tivities of auflientic cellular IL-10 (MacNeil ef al, 1990; de Waal 
Malefyt ef al, 1991b), which makes vIL-10 potentially a more 
potent immunosuppressant. 
Gene ttansfer and gene tiierapy for ttansplantation, which aug-
ment tiie production of immunosuppressive cytokines witiiin the 
allograft, may markedly impair effective antigen presentation, re-
duce or eUminate immunogenicity, and prevent rejection or pro-
long graft survival while avoiding tiie systemic toxicity of con-
ventional immunosuppression. Previous smdies from our 
laboratory have shown that a variety of plasmid and viral (retto-
virus, herpesvmis, adenovirus) vectors can successfully ttansfer 
and express exogenous genes m cardiac allografts (Qin ef al, 
1995). In particular, a rettoviral vector encoding vIL-10 induced 
local immunosuppression and significantiy prolonged allograft 
survival. Prolongation of graft survival was associated with spe-
cific inhibition of donor-specific cytotoxic T lymphocytes (CTL) 
and IL-2-producing helper T lymphocytes, and inhibition of lym-
phocytic infilttation mto the graft (Qin ef al, 1996). The prob-
lem remains that although aUograft survival is prolonged, it is not 
indefinite and tolerance has not been achieved. This is Ukely due 
to the fact that gene ttansfer is inefficient and expression is low 
and ttansient (Qin ef al, 1995). Gains in allograft survival, tiiere-
fore, require improvements in gene ttansfer and expression so that 
the immunosuppressive cytokines can be produced at higher 
amounts for longer periods of time. However, the use of rettovi-
ral vectors is restricted by their relatively low titer, low ttansfec-
tion efficiency, requirement for target cell repUcation, and the po-
tential for maUgnant ttansformation of tiie target (Gordon and 
Anderson, 1994). In this sttidy, we investigated die feasibility of 
using an adenoviral vector for improved ttansgene expression. 
Adenoviral vectors are efficient for in vivo delivery of genes 
to a wide variety of tissue types and do not require target cell 
repUcation (Trapnell and Gorziglia, 1994; Bramson ef al, 
1995). Adenoviral vectors can accept exogenous D N A up to 
7.5 kb in size and be easily produced in high titer (Trapnell and 
GorzigUa, 1994; Bramson ef al, 1995). The major disadvan-
tage of adenoviral vectors is that the duration of expression is 
limited by the potent adenovirus-specific immune response di-
rected to the infected cell (Yang ef al, 1994a,b; Dai ef at., 
1995). In this smdy, we also investigated whether gene trans-
fer of vIL-10 could inhibit the host immune response against 
the adenoviral vector. 
MATERIALS AND METHODS 
Mice 
CBA/J (H-2'') and C57BL/6J (H-2'') female mice (8-10 
weeks of age) were purchased from The Jackson Laboratory 
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(Bar Habor, ME). Timed pregnant C57BL/6 were purchased 
from Harlan-Sprague-Dawley, Inc. (Indianapolis, IN). 
Adenoviral vectors 
All vectors are El deleted. AdHCMV)3-gal encoding P-
galactosidase ()3-Gal) under the conttol of the human cy-
tomegalovirus ( C M V ) immediate early promoter, and 
AdSV40vIL-10 encoding vIL-10 under the conttol of SV40 
early promoter were produced as previously described (Csete 
et al, 1994). Ad5, a control wild-type adenoviral vector with-
out inserts or deletions, was provided by Dr. M . Imperiale (Uni-
versity of Michigan Medical Center). A d H C M V h A P encoding 
human alkaline phosphatase under the conttol ofthe human cy-
tomegalovirus ( H C M V ) promoter, was obtained from vector 
core of U M M C . A U vectors were adjusted to 1 X 10'" pfu/ml. 
Antibodies and cell lines 
The JES3-19F1.1 rat anti-human IL-10 (Bacchetta ef al, 
1994) hybridoma was purchased from the A T C C (Rockville, 
M D ) ; the 12-15 rat anti-murine C D 2 hybridoma (Altevogt ef 
al, 1989) was a gift of Dr. P. Altevogt. These two hybridomas 
were grown in culture and purified over protein G columns 
(Pharmacia-LKB, Piscataway, NJ). The L929 mouse fibroblast 
cell line (H-2'') (Ruff and Gifford, 1981) was purchased from 
the A T C C . 
Cardiac transplantation 
The heterotopic, nonvascularized cardiac ttansplantation 
model was used (Qin ef al, 1995, 1996). Donor neonatal 
C57BL/6 mice were sacrificed and whole hearts were removed 
and placed in the subcutaneous position of the ear pinnae of 
CBA/J or C57BL/6 recipients. One X 10* pfu of adenovttal 
vector in 10 pl was dttectiy injected into the graft at the time 
of ttansplantation and/or 10 days after ttansplantation. JES3-
19F1.1 m A b was injected inttavenously at 100 pg every other 
day for six doses. 12-15 m A b was injected inttavenously at 100 
pg on the day of ttansplantation (day 0) and 1 day after ttans-
plantation (day 1). m A b s were in 0.5-ml volumes in phosphate-
buffered sahne (PBS). Survival of cardiac allografts was fol-
lowed with E K G monitoring (Polygraph 78 Series wifli preamp 
and filters. Grass Instruments, Quincy, M A ) every other day. 
Cessation of cardiac electrical activity was the determinant of 
rejection. There were at least 4 nuce per group. Statistical com-
parison was performed with Smdent's f test. 
CTL assay 
The C T L assay was performed as described (Yang ef al, 
1994a; DeMatteo ef al, 1995) and modified as follows. 
C57BL/6 to CBA/J ttansplantation was performed as described 
above and graft-infilttating lymphocytes (of CBA/J recipient 
origin) were isolated 10 days after ttansplantation, plated at 1 X 
10* cells per well in 24-well plates, and co-cultiu-ed with 4 X 
10*, 2,000 rad, y-irradiated CBA/J splenocytes in the presence 
of 1 5 % 2 m M a-methyl mannoside-treated concanavalin A 
(ConA) supernatant [from 3-day ConA- (5 ̂ tg/ml) stimulated 
mouse spleens (2 X 10* cells/ml)]. Naive CBA/J mice were in-
jected inttavenously with 1 X 1 0 * pfu of adenoviral vector and 
splenic lymphocytes were isolated at 7 and 21 days after in-
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jection and plated at 5 X 10* cells per well in 24-well plates. 
All cultures were stimulated with AdS or AdHCMV/3-gal at a 
multiplicity of infection (moi) of 10 for 5 days. Adenovirus-
specific cytotoxic activity was assessed in a 4-hr, ̂ 'Cr release 
assay with AdS or AdHCMV;3-gal-infected L929 as target, 
which was infected with AdS or AdHCMV/3-gal at an moi of 
SO 1 day prior to assay. 
ELISA for IL-2, IL-4, IL-10, and IFN-y 
CTL culture supematants were harvested after 3 days, and 
two-antibody capture enzyme-linked immunosorbent assays 
(ELISAs) for IL-2, IL-4, IL-10, and IFN-y were performed as 
recommended by the manufacture (Pharmingen, San Diego, 
CA). Ninety-six well flat-bottomed plates were coated with 50 
pl of anti-cytokine capture monoclonal antibodies (mAbs) at 2 
/ag/ml in 0.1 M NaHCOs ovemight at 4°C. Plates were washed 
with 0.05% Tween-20 in PBS, blocked with 200 pl of 3 % 
bovine semm albunun (BSA) in PBS for 2 hr at room temper-
ature, washed, standards and culture supematants added, and 
incubated ovemight at 4°C. Plates were again washed, incu-
bated with 100 pl of biotinylated anti-cytokine-detecting mAbs 
at 1 /itg/ml for 45 min at room temperature, washed, 100 pl of 
a 1:1,000 dilution of peroxidase-conjugated streptavidin 
(Kirkegaard & Perry, Gaithersburg, M D ) added to each well, 
and incubated at room temperature for 30 min. Plates were 
washed, 100 pl of freshly prepared 2,2'-azino-bis 3-ethyl-
benzthiazoUne-6-sulfonic acid (ABTS) solution (Kttkegaard & 
Perry) added to each weU, incubated at room temperature, and 
stopped by adding 100 pl of 1 % SDS. Plate O.D.s were mea-
siu-ed at 405 m m . Purified recombinant cytokines (Pharmingen) 
were used as standards. 
X-Gal staining 
C57BL/6 syngeneic ttansplantation was performed as de-
scribed above and the grafts were injected with 5 X 10^ pfu of 
AdHCMp-gal in combination with 5 X IO'' pfu of either AdS 
or AdSV40vIL-10. The ears with ttansplanted hearts were har-
vested at various time points after ttansplantation, quick-frozen, 
embedded in O.C.T. (Miles Scientific, Naperville, IL), sec-
tioned at 10 pm, collected onto gelatin-coated glass sUdes, fixed 
at room temperature in 0.25% glutaraldehyde in PBS for 30 
min, rinsed three times in PBS for a total of 30 min, and incu-
bated at 37°C ovemight in 0.5 mg/ml 5-bromo-4-chloro-3-in-
dolyl-/3-D-galactopyranoside (X-Gal) solution containing 5 m M 
potassium ferrocyanide, 5 m M potassium ferricyanide, 2 m M 
MgCla, 1 m M spermidine, 0.02% Nonidet P-40, and 0.01% 
sodium deoxycholate in PBS. After staining, the sections were 
fixed with 4 % formaldehyde and counterstained with eosin (Qin 
etal, 1996). 
RESULTS 
Adenoviral vector vIL-10 gene transfer prolongs 
allograft survival 
Allografts injected witfi AdSV40vIL-10 at 1 X 10* pfu/graft 
at the time of ttansplantation (day 0) showed mild prolongation 
of graft survival from 14.2 ± 1.0 days to 18.4 ± 1.2 days (Fig. 
1), although this did not reach statistical significance (p> 
0.01). This dose of adenoviral vector is not toxic nor does it 
cause cytopathic effects to the graft because syngeneic grafts 
injected with the same dose of this vector had indefinite sur-
vival up to 150 days (now shown). Reducing the dose of adeno-
viral vector to 1 X 10^ or 1 X 10* pfu/graft produced no pro-
longation of graft survival (Fig. 1). This effect on graft survival 
is far less than that provided by administering 5 X 1 0 ^ pfu/graft 
of a rettovttal vector encoding vIL-10, which prolonged graft 
survival to 39.4 ± 2.5 days (Qin ef al, 1996). This difference 
is likely due to the different expression profiles of genes ttans-
ferred by these two different vectors as a result of differences 
in promoters and immunogenicity (Qin et al, 1995). For ex-
ample, using the LacZ reporter gene, we previously demon-
strated that the adenovttal vector AdHCMV/3-gal ttansferred 
intense expression of /3-Gal for only a short period of time to 
CBA/J syngeneic cardiac grafts. The highest expression was 
observed 5 days after gene transfer, with up to 3 0 % of cells 
stained by X-Gal. Thereafter, the number of positive cells de-
cUned rapidly. Only 5 % of cells showed positive staining 10 
days after gene transfer, and none of the cells were positive by 
15 days after gene transfer (Qin ef al, 1995). In conttast, when 
the rettoviral vector CRIP-MFG-LacZ was administered, /3-Gal 
expression could be observed even 30 days after gene ttansfer, 
although fewer than 1% cells were positive (Qin ef al, 1995). 
These results suggest that prolonged allograft survival requires 
expression of even low levels of vIL-10 for an extended period 
of time. Therefore, we administered a second dose of the ade-
noviral vector 10 days after ttansplantation, a time at which the 


















—•-- Untreated (n=5) 
- -• - AdSV40vlL-10 (1 X10^ pfu/graft) day 0 (n=12) 
— o — AdSV40vlL-10 (1 x ICP pfu/graft) day 0,10 (n=11) 
— A r — AdSV40vlL-10 (1 X10^ pfu/graft) day 0 (n=4) 
— • — AdSV40viL-10 (1 X10* pfu/graft) day 0 (ns5) 
FIG. 1. AdSV40vIL-10 prolongs allograft survival. C57BL/6 
hearts were transplanted to CBA/J recipients. AdSV40vIL-10 
in 10 /xl was directiy injected into the allograft at the doses in-
dicated at the time of transplantation (day 0) and/or 10 days 
later (day 10). Survival of cardiac allografts was followed by 
E K G monitoring every other day. AdSV40vIL-10 significantiy 
prolonged allograft survival only when the vector was admin-
istered for two doses both on the day of ttansplantation and 10 
days later. 
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body response was not yet measurable (not shown), but ex-
pression of the fttst adenoviral vector inoculum was reduced 
but not completely eUminated. This tteatment significantly pro-
longed graft survival to 32.2 ± 1.7 days (p < 0.001) (Fig. 1). 
Additional injections of AdSV40vIL-10 were not performed, 
because significant titers of adenovims-specific neuttaUzing an-
tibodies developed 21 days after a single injection of the ade-
novttal vector (not shown), and this was expected to limit the 
efficacy of further repeated injections of AdSV40vIL-10. These 
resuhs with two adnunisttations of AdSV40vIL-10 are similar 
to those with a single administration of rettoviral vIL-10 gene 
delivery and demonsttate that adenovims-mediated gene ttans-
fer of vIL-10 significantiy prolongs allograft survival only when 
the vector is administered for two doses, both on the day of 
ttansplantation and 10 days later. This also implies that ex-
pression from the first vttal inoculum was Umited by nonim-
mune mechanisms, because the second inoculum was able to 
extend graft survival, which would not have been expected if 
there was a significant anti-adenovttal immune response. 
Prolongation of allograft survival is due to vIL-10 
expression 
The specificity of vIL-10 gene ttansfer was determined. 
Wild-type adenovims have unique ways of escaping from host 
immature surveiUance by producing an E3 region protein that 
down-regulates M H C class I expression on the cell surface and 
thus reduces lysis ofthe infected ceUs by CTL (Wold and Good-
ing, 1991). Even though the recombinant adenoviral vectors 
lack El protein and the ttanscription of E3 protein is at a very 
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—*-- Untreated (n=5) 
— o — AdSV40vlL-10 day 0,10 {n=11) 
- -o - AdSV40vlL-10 dayO/AdHCMVp-gal day 10 (n=4) 
— • — AdHCMVP-gal day 0/AdSV40vlL-10 day 10 (n=4) 
— A — JES3 (n=4) 
— A — AdSV40vlL-10dayO, 10/JES3(n=5) 
FIG. 2. The prolongation of allograft survival by two se-
quential doses of AdSV40vIL-10 is due to vIL-10 expression. 
AdSV40vIL-10 and/or AdHCMV^-gal were dttectiy injected 
into the allograft at 1 X 10* pfu per graft at the time of trans-
plantation (day 0) and 10 days later (day 10). The vIL-10-neu-
traUzing antibody JES3-19F1.1 was injected intravenously at 
100 /xg every other day for six doses. 
doses of adenovttal vectors, the expression of E3 protein, rather 
than vIL-10, could inhibit the immune response against allo-
antigens. To test this possibility, AdSV40vIL-10 was adminis-
tered at time of ttansplantation (day 0) and AdHCMV/8-gal 10 
days after ttansplantation (day 10), or AdHCMV/8-gal was ad-
ministered day 0 and AdSV40vIL-10 on day 10. Bofli of these 
tteatments produced no significant survival advantage com-
pared to a single dose of AdSV40vIL-I0 (Fig. 2). Thus, aden-
ovttal vectors alone did not prolong graft survival, suggesting 
tiiat vIL-10 rather than E3 gene deUvery was required for im-
munosuppression. The specificity of vIL-10 was fiirther con-
firmed by administering anti-vIL-10 m A b (JES3-19F1.1, a neu-
ttaUzing antibody that cross-reacts with human IL-10 and 
vIL-10 but not mIL-10) to the transplant recipients after vIL-
10 gene ttansfer. This tteatment abrogated the effect of se-
quential administtation of AdSV40vIL-10 and reduced graft 
survival to 15.2 ± 1.3 days (Fig. 2). These results demonsttate 
that AdSV40vIL-10 gene ttansfer specifically prolongs allo-
graft survival through expression of vIL-10 protein over an ex-
tended period of time. 
vIL-10 gene transfer prevents adenovirus-specific CTL 
priming in graft infiltrating cells 
Previous results (Qin ef al, 1996) show that vIL-10 gene ttans-
fer prolongs allograft survival and is associated with the inhibi-
tion of allospecific CTL responses. M H C class I-restricted CDS"*" 
T ceUs also play a centtal role in host antiviral immune responses 
by either dkect CTL-mediated lysis of infected cells or secretion 
of cytokines, such as IFN-y, which influence viral gene expres-
sion (Doherty ef al, 1992; Yang ef al, 1994b). Therefore, ttie 
effect of vIL-10 on adenoviras-specific CTL activity was next 
investigated. Graft-infilttating cells were obtained 10 days after 
ttansplantation and gene ttansfer, restimulated in vitro with AdS-
infected syngeneic spleen ceUs for 5 days, and assayed for ade-
novims-specific CTL activity by a 4-hr ̂ 'Cr release assay using 
AdS-infected L929 (H-2'') targets. The results demonsttate fliat 
in vivo tteatment with AdHCMVj8-gal faciUtated the generation 
of adenovims-specific CTL, whereas tteatment of AdSV40vIL-
10 prevented CTL priming (Fig. 3). This experiment was per-
formed three times with sinular results. 
vIL-10 gene transfer inhibits systemic adenovirus-
specific immunity 
The data in Fig. 3 show that vIL-10 gene ttansfer inhibits 
adenovttus-specific CTL generation. A potential problem witii 
flie experiment is that two vectors with different promoters were 
used. Thus, the minor differences in vector stmcture might 
cause some difference in CTL generation even tiiough bodi vec-
tors were generated from adenovims type 5 wifli El region dele-
tion, and were propagated and prepared in the same way. As 
an altemative way of evaluating titis issue, mice were injected 
intravenously with the combination of adenoviral vector AdS 
plus AdHCMV/3-gal, A d H C M V h A P plus AdHCMV/8-gal, or 
AdSV40vIL-10 plus AdHCMV/3-gal. Anti-vIL-10 m A b JES3-
19F1.1 was also administered to animals tiiat received 
AdSV40vIL-10 plus AdHCMV/3-gal to confrnn tiie specificity 
of vIL-10. Splenic lymphocytes were harvested 7 and 21 days 
after injection, restimulated in vitro witii AdHCMV/3-gal-in-
fected stimulators, and assayed for adenovims-specific CTL ac-
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FIG. 3. Vttal IL-10 gene ttansfer inhibits adenovims-specific 
C T L printing in graft-infilttating lymphocytes. CBA/J recipi-
ents were ttansplanted with CS7BL/6 hearts injected with 1 X 
10* pfu of the indicated adenovttal vectors. Graft infiltrating 
ceUs were harvested 10 days after ttansplantation, restimulated 
in culture with syngeneic (CBA/J) splenocytes infected with 
AdS, and assayed for C T L activity using AdS infected L929 as 
targets. At least 10 allografts were used for each group for each 
experiment. The experiment was repeated three times with sim-
ilar results. 
tivity with AdHCMV/3-gal-infected targets. The results show 
that vIL-10 gene ttansfer inhibited the generation of adeno vi-
ral-specific CTL, and anti-vIL-10 administtation prevented this 
inhibition (Fig. 4). The inhibition of C T L by vIL-10 is also as-
sociated with a significant decrease in IFN-y production in the 
culture supematant (Fig. 5), whereas IL-2, IL-4, and IL-10 pro-
duction remain at low levels and unchanged (not shown). De-
spite inhibiting adenovims-specific C T L activity, vIL-10 gene 
ttansfer did not alter adenovims-specific proliferative T cell re-
sponses in vitro (not shown). 
vIL-10 gene transfer results in extended adenovirus-
mediated reporter gene expression 
Because vIL-10 gene ttansfer and expression prolonged al-
lograft survival and inhibited tfie C T L and T H I response to ade-
noviral vector, it was important to determine if gene ttansfer 
would also prolong expression of a reporter gene deUvered by 
tfie adenovims. C57BL/6 syngeneic ttansplantation was per-
formed into C57BL/6 recipients and the grafts were injected 
with AdHCMV/8-gal in combination with eitiier AdS or 
AdSV40vIL-10. The ears witfi ttansplanted hearts were har-
vested 5, 10, and 20 days later, and jS-Gal expression was de-
termined by X-Gal staining. Both groups revealed intense ̂-
Gal expression 5 days after gene ttansfer (Fig. 6A,B), with more 
than 3 0 % of ceUs stained by X-Gal. By day 10, tiie /3-Gal ex-
pression in die Ad5/AdHCMV/3-gal group was dramatically de-
creased, with less than 5 % of tfie ceUs positive (Fig. 6C), 
whereas j8-Gal expression in tiie AdSV40vIL-10/AdHCMV;8-
gal group decreased more slowly, with 1 5 % of the cells still 
positive (Fig. 6D). Twenty days after gene ttansfer, the AdS/Ad-
HCMV/3-gal group showed no j3-Gal expression (Fig. 6E,G), 
whereas tfie AdSV40vIL-10/AdHCMV/3-gal group maintained 
j3-Gal expression in a significant number of cells (Fig. 6F,H). 
Therefore, adenovims-mediated gene ttansfer and expression of 
vIL-10, which inhibit the immune response to adenovttal anti-
gens, are sufficient to improve the persistence of vector and 
ttansgene containing cells and result in substantially longer 
transgene expression. 
Inhibition ofT cell function by anti-CD2 mAb does 
not synergize with AdSV40vIL-10 to prolong allograft 
survival 
The results demonstrate that prolongation of allograft sur-
vival requttes continuous expression of vIL-10 for an extended 
period of time (Fig. 1). Because T cells are the primary effec-
tors mediating both aUograft destmction and vttal clearance 
(Yang et al, I994a,b; Dai ef al, 1995), inhibition of T cell ac-
tivity by administration of other immunosuppressants may im-
prove adenovttal vector persistence and allow longer vector 
function and ttansgene expression (Engelhardt ef al, 1994; Dai 
ef al, 1995; Dematteo et al, 1996). Other immunosuppressants 
may therefore synergize with AdSV40vIL-10 to prolong allo-
graft survival. The anti-CD2 m A b 12-15 has previously been 
shown in our model to inhibit a wide variety of both CD4"''-
and CD8+-mediated cellular events (Chavin ef al, 1994; Qin 
et al, 1994). W e tested whether anti-CD2 m A b could syner-
gize with AdSV40vIL-10 to prolong allograft survival by in-
hibiting multiple T cell responses. AdSV40vIL-10 was injected 
into allografts on day 0 and 100 /xg of anti-CD2 m A b , a dose 
known to be optimal for inhibition of C D 4 and C D 8 T cell im-
munity, was injected inttavenously into allograft recipients on 
day 0 and day 1. The combination of AdSV40vIL-10 and anti-
C D 2 m A b prolonged graft survival to 26.4 ± 2.8 days (n = 5), 
which was not significantly different compared to anti-CD2 
m A b alone (24.4 ± 1.0 days) (Qin ef al, 1994) and not as ef-
fective as two sequential doses of the adenovttal vector. This 
result suggests that despite dual immunosuppression by anti-
C D 2 m A b and vIL-10 at the time of allografting, inhibition of 
C D 4 + and C D 8 + T ceUs and A P C was not sufficient to pre-
vent the attenuation or extinction of expression of the ttans-
ferred vIL-10 gene from the single inoculum of viral vector. 
This result and the readministtation resuks both imply that im-
mune destmction of infected cells is not the sole mechanism of 
ttansgene extinction and fliat nonimmune phenomena Umit 
ttansferred gene expression by affecting promoter function or 
disposition of episomal D N A (Tsui ef al, 1995; Guidotti ef al, 
1996; Yao ef al, 1996; Worgall ef al, 1977). W e also have fur-
ther evidence in our model that despite the lack of reporter gene 
expression, vector D N A persists (unpublished resuUs), which 
agrees with the findings of others (Dwarki ef al, 1995; Yao ef 
al, 1996). 
D I S C U S S I O N 
Adenoviral vectors are atttactive for gene ttansfer because 
of thett broad host range, capacity for large D N A inserts, and 
high titers. However, the in vivo application of first-generation 
recombinant adenovttuses (with El deletion) is Umited by host 
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FIG. 4. Vttal IL-10 gene transfer inhibits adenovims-specific CTL generation in splenic lymphocytes. CBA/J mice were in-
jected inttavenously with 2 X 10* pfu of the indicated combination of adenovttal vectors. The vIL-10-neuttalizing antibody JES3-
19F1.1 was injected intravenously at 100 pg every other day for six doses. Seven and 21 days later, splenic lymphocytes were 
isolated, restimulated in culture with AdHCMV/3-gal, and assayed for C T L activity using AdHCMV/3-gal-infected L929 as tar-
gets. Four animals were used for each group at each time point. The experiment was repeated three times with similar results. 
untreated 
AdHCMVhAP/AdHCMV^al day 7 
AdSV40viL-10/AdHCMV^al day 7 
AdHCMVhAP/AdHCMVp^al day 21 
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FIG. 5. Vttal IL-10 gene ttansfer inhibits adenovims-induced IFN-y production. Culture supematants were harvested after 3 
days, and two-antibody capture ELISA for IFN-y was performed. 
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FIG. 6. Viral IL-10 gene transfer induces extended reporter 
gene expression. C57BL/6 syngeneic ttansplants were per-
formed and the grafts were injected with S X 10^ pfu of 
Ad5/AdHCMV/3-gal (A, C, E, and G ) or AdSV40vIL-10/Ad-
HCMV/3-gal (B, D, F and H). The ears with ttansplanted hearts 
were harvested S (A, B), 10 (C, D ) , and 20 (E, F, G, and H ) 
days later for X-Gal stairung. Original magnification: 100 X 
(A-F) and 250 X (G and H ) . There are at least three grafts for 
each group at each time point. 
antiviral immune responses (Yang ef al, 1994a,b; Dai ef al, 
1995). Recombinant adenoviral vectors express low levels of 
vtial genes that stimulate cellular responses, which involve 
C D 8 + CTL, C D 4 + T H I cells, IFN-y, and IL-2 (Doherty ef al, 
1992; Yang ef al, 1994b) and lead to desttiictive inflammation 
and transient ttansgene expression. Several approaches have 
been taken to cttcumvent the immune response to adenoviral 
vectors. One approach is to engineer a less immunogenic vec-
tor by furflier deletion of the E2 region from the adenovttal 
genome (Engelhardt ef al, 1994; Yang ef al, 1994c). However, 
as furtiier deletions are made in the adenoviral genome, the viras 
becomes more difficult to propagate and obtain in high titer 
(Engelhardt ef al, 1994). 
Another approach is to suppress the immune system of the 
host by using immunosuppressive drags such as cyclophos-
phamide (Dai ef al, 1995) and cyclosporine A (Engelhardt ef 
al, 1994; Dai ef al, 1995), or depleting C D 4 + T cell (Demat-
teo ef al, 1996). Unfortunately, the systemic adnunisttation of 
these immunosuppressants will affect systenuc immune func-
tion and result in a number of complications, such as infection 
and malignancy, and otiier undesttable side effects, which make 
it less atttactive for cUnical application. 
The third approach is to induce unresponsiveness to ade-
noviral antigens by intrathymic inoculation (DeMatteo ef al, 
1995). The involuted thymus of adult humans make this ap-
proach not feasible for human gene therapy. 
A fourth approach is to induce local immunosuppression by 
generating adenoviral vectors that constitutively express im-
munomodulatory molecules, such as the 19K glycoprotein (gp 
19K) found in the adenoviral E3 region (Lee ef al, 1995), or 
the interleukin-1 receptor antagonist (IL-IRa) (McCoy ef al, 
1995). However, expression of IL-IRa is unable to prevent ade-
noviral vector-induced inflammation (McCoy ef al, 1995). 
IL-10 is a potent immunosuppressive cytokine that has a va-
riety of negative effects on IFN-y production, CDS"^ CTL, and 
CD4"^ THI cells activities, all of which have been shown to be 
important effectors for host antivttal immune responses (Do-
herty ef al, 1992; Yang ef al, 1994b). In addition, IL-10 shows 
antiinflammatory activity by inhibiting the production of proin-
flammatory cytokines, such as IL-1;S, IL-6, IL-8, TNF-a (de 
Waal Malefyt ef al, 1991a; Fiorentino ef al, 1991; Ding and 
Shevach, 1992), and up-regulating the human monocyte pro-
duction of soluble T N F receptors and IL-IRa (CassateUa ef al, 
1993). Therefore vIL-10 may be a more potent immunosup-
pressive molecule compared to IL-IRa, which competes with 
IL-la and IL-l/S for binding to the IL-1 receptor (CassateUa ef 
al, 1993), and gp 19K of adenoviras E3 region, which binds 
to class I antigens to block the transport of M H C class I to the 
cell surface (Wold and Gooding, 1991). 
In this study, we tested the feasibiUty of using an adenovi-
ral vector encoding vIL-10 to induce local immunosuppression 
within aUografts to prolong allograft survival and suppress host 
antiadenoviral immune responses. The results demonsttate that 
adenoviras-mediated gene ttansfer and expression of vIL-10 
may not prolongs murine cardiac allograft survival, but also in-
hibits the immune response toward adenovttal antigens, and 
thereby improves the persistence of the vector and extends 
ttansgene expression. These findings could be used to design a 
new adenoviral vector that express both an immunosuppressive 
cytokine gene and another gene of interest. Altematively, two 
different vectors could be administered simultaneously. This 
strategy should have general appUcations in many gene therapy 
settings other than transplantation. 
Previously, we demonstrated that a variety of plasmid and 
viral (retrovims, herpesvims, adenoviras) vectors successfully 
transferred and expressed exogenous genes in cardiac trans-
plants (Qin ef al, 1995). The duration and the distribution of 
transferred gene expression depended on vector characteris-
tics (Qin ef al, 1995). For retroviral vectors, expression was 
low but relatively prolonged. A retroviral vector encoding 
vIL-10 significantly prolonged allograft survival by inducing 
local immunosuppression, which was associated with specific 
inhibition of the recraitment and/or generation of donor-spe-
cific C T L and IL-2-producing helper T lymphocytes within 
the grafts, and inhibition of lymphocytic infiltration within the 
graft (Qin ef al, 1996). In contrast, a single injection of vIL-
10 protein at the time of transplantation had no effect on al-
lograft survival (Qin ef al, 1996). 
In this study, we demonstrated that a single administtation 
of adenoviral vector encoding vIL-10, which presumably pro-
vided high-level vIL-10 protein expression for only a short 
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period of time, was also not sufficient to prolong allograft sur-
vival (Fig. 1). Adenovims-mediated gene ttansfer of vIL-10 
significantly prolonged allograft survival only when the vec-
tor was administered for two doses, both on the day of trans-
plantation and 10 days later (Fig. 1). Because cytokine pro-
teins normally have a very short half-life, high-level 
expression of vIL-10 for only a short period after transplan-
tation would not be expected to be sufficient to inhibit allo-
graft rejection. These results all suggest that prolonged ex-
pression of the gene product, which provides locaUzed 
immunosuppressive effects within the graft, is needed for im-
proved graft survival. 
It is important to note that the immune response toward 
adenoviral antigens is probably just one of the mechanisms 
that lead to short-term transgene expression. Many experi-
ments demonstrate that even by using less immunogenic E2-
deleted adenovttal vectors (Engelhardt ef al, 1994; Yang ef 
al, 1994c), immunosuppressants to inhibit the host immune 
system (Engelhardt ef al, 1994; Dai cf al, 1995; Dematteo ef 
al, 1996), or immunodeficient mice (Dematteo ef al, 1995) 
lacking C D 8 + T cells ( M H C class I-deficient mice), C D 4 + T 
cells ( M H C class Il-deficient mice), or both T and B cells 
(SCID mice), ttansgene expression improved, but was not sus-
tained at high levels. Likewise the results here show that de-
spite inhibiting T ceU immune responses with vIL-10 or anti-
C D 2 m A b , transgene expression was still limited. The abiUty 
to readminister AdSV40vIL-10 and achieve prolonged graft 
survival also suggests nonimmune limitations to ttansgene ex-
pression. Others (Dwarki ef al, 1995; Yao ef al, 1996) have 
shown persistence of vector D N A despite the lack of trans-
gene expression. Even using retroviral vectors, which incor-
porate into the genome and theoretically could result in per-
manent transgene expression, indefinite gene expression is 
only achieved in vitro but not in vivo (Scharfmann ef al, 1991; 
ChaUita and Kohn, 1994; Rettinger et al, 1994), especially 
when strong viral promoters are used. 
These results all suggest fliat nonimmune, noncytolytic 
mechanisms are significant determinants of ttansgene expres-
sion. Recent evidence suggests that cytokines produced by spe-
cific or nonspecific immune responses may Umit gene expres-
sion by negatively regulating transcriptional activity, 
ttanslational rates, or m R N A tumover from certain viral pro-
moters or enhancers (Tsui ef al, 1995; Guidotti ef al, 1996; 
Yao ef al, 1996; Worgall ef al, 1997). In particular, these stud-
ies showed that promoter extinction, attenuation, or inactiva-
tion may occur without kilUng the vims-infected cells. Indeed, 
we have preUminary data suggesting that certain cytokines af-
fect promoter expression from vttal vectors (L.Q., J.S.B., un-
published data). Therefore, the smdy of promoter stracmre and 
an understanding of cytokine-ttanscription factor-promoter in-
teractions will likely be requtted to improve these aspects of 
gene therapy. 
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